Otezla (Apremilast) Patent Expiration, LOE Window & CMS Spending

Otezla (Apremilast) by Amgen: FDA Orange Book core substance LOE 2028-08-16 (last listed 2034-11-29), 5 AB generics, $1.39B 2024 CMS Part D & Medicaid spend, and 14 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAmgen
FDA Application & PathwayN205437 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2028-08-16
Last Listed Patent or Exclusivity Date2034-11-29
Orange Book Patents (*PED Extensions)8 patents (4 *PED)
Active AB-Rated Generic Competitors5
2024 CMS Total Public Spend$1.39B
2024 Medicare Part D Spend$1.05B
2024 Medicaid Spend$342.3M
Reported Wholesale Price Change (CA SB 17)14 WAC filings (max 28.1% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Amgen across sibling Meru public-data platforms.